Head-to-head evidence
Eslicarbazepine acetate vs Oxcarbazepine (Oxtellar XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
The main study was randomized, quadruple-blind, placebo-controlled, and included 402 participants, with seizure frequency as a clinical primary endpoint. Although seizure frequency was lower in all eslicarbazepine groups than with placebo, the posted registry data do not state whether the prespecified primary comparison was statistically significant, so the result remains unclear.
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Oxcarbazepine (Oxtellar XR)'s landscape